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Objective: To evaluate the effect of a clinical trial
question prompt list in patients considering enrolment
in cancer treatment trials.
Setting: Tertiary cancer referral hospitals in three state
capital cities in Australia.
Participants: 88 patients with cancer attending three
cancer centres in Australia, who were considering
enrolment in phase 3 treatment trials, were invited to
enrol in an unblinded randomised trial of provision of a
clinical trial question prompt list (QPL) before
consenting to enrol in the treatment trial.
Interventions: We developed and pilot tested a
targeted QPL for patients with cancer considering
clinical trial participation (the clinical trial QPL).
Consenting patients were randomised to receive the
clinical trial QPL or not before further discussion with
their oncologist and/or trial nurse about the treatment
trial.
Primary and secondary outcomes: Questionnaires
were completed at baseline and within 3 weeks of
deciding on treatment trial participation. Main outcome
measure: scores on the Quality of Informed Consent
questionnaire (QuIC).
Results: 88 patients of 130 sought for the study were
enrolled (43 males), and 45 received the clinical trial
QPL. 49% of trials were chemotherapy interventions
for patients with advanced disease, 35% and 16%
were surgical adjuvant and radiation adjuvant trials
respectively. 70 patients completed all relevant
questionnaires. 28 of 43 patients in the control arm
compared with 39 of 45 patients receiving the clinical
trial QPL completed the QuIC (p=0.0124). There were
no significant differences in the QuIC scores between
the randomised groups (QuIC part A p=0.08 and QuIC
part B p=0.92). There were no differences in patient
satisfaction with decisions or in anxiety levels between
the randomised groups.
Conclusions: Use of a question prompt list did not
significantly change the QuIC scores in this
randomised trial. ANZCTR 12606000214538
prospectively registered 31/5/2006.
Trial registration number: Results,
ACTRN12606000214538.
INTRODUCTION
Surveys of the public have found widespread
support for the concept of clinical trials as
an important and ethical means of develop-
ing improved medical care. However, only a
small percentage of eligible patients are
recruited to clinical trials in many institutions
that promote clinical trial participation.
A signiﬁcant proportion of non-trial par-
ticipation is explained by patient refusal.1
Reasons for trial refusal by eligible patients
include concerns regarding experimentation
and uncertainty and loss of control over
treatment decisions. Even when patients
agree to participate, they frequently do not
understand basic components of the trial
that they have consented to enter.2 3 In the
UK Jenkins et al4 audiotaped discussions
between oncologists and patients during
which consent was being obtained for a ran-
domised clinical trial. In most, the concept
of the trial was introduced by describing
Strengths and limitations of this study
▪ The clinical trial question prompt list contained
51 questions grouped under 10 headings.
▪ The Quality of Informed Consent questionnaire
(QuIC) is widely used to measure clinical trial
participants’ actual and perceived understanding
of cancer clinical trials.
▪ The trial was stopped prematurely due to low
accrual rates and on the advice of an independ-
ent data monitoring committee.
▪ Participants had only a few minutes to review the
clinical trial question prompt list (QPL) before
continuing discussion about the randomised
cancer treatment trial.
▪ Information about the duration of the informed
consent discussion in the trial is not available.
▪ The time patients receiving QPL list had to
review the QPL before continuing the discussion
about the cancer treatment is not available.
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uncertainty about treatment decisions. The word ran-
domisation was mentioned in 51 consultations (62.2%).
The median duration of ‘consent’ interviews was
<15 min and most patients signed the consent document
at the ﬁrst consultation at which the clinical trial was
discussed.
Brehaut et al5 6 argue that the existing approach to
obtaining informed consent for clinical research may be
improved by using decision aids. Juraskova et al7
reported successful piloting of a decision aid to assist
women considering participation in a breast cancer pre-
vention trial. Spiegle et al8 performed a systematic review
to identify alternative types of decision support interven-
tions (DSIs) for cancer treatment and a meta-analysis to
compare the effectiveness of DSIs compared with
patient decision aids. The study showed that the effect-
iveness of other DSIs, including question prompt list
(QPLs) and audio recordings of the consultation, is
similar to patient decision aids. This ﬁnding is important
because less complex DSIs such as a targeted QPL may
be all that is necessary to achieve similar outcomes as
patient decision aids for cancer treatment. QPLs have
been shown to increase question asking in patients with
cancer.9 10
The Quality of Informed Consent questionnaire
(QuIC) was designed to measure participants’ actual
(objective) and perceived (subjective) understanding of
cancer clinical trials. Joffe et al11 derived 13 independent
domains of informed consent and wrote one or more
questions to measure participants’ objective and subject-
ive understanding of their clinical trials. After feedback
from pilot testing and input from expert panels, the
QuIC was sent to adult patients with cancer enrolled in
phase 1, 2 and 3 clinical trials. Test–retest reliability was
good, as was face and content validity. The QuIC took
an average of 7.2 min to complete.
Joffe et al2 reported the use of the QuIC to measure
the quality of understanding among 207 cancer clinical
trial participants in Boston who had signed a clinical
trial consent form a median of 16 days earlier. Almost
half of the consent discussions had lasted 1 hour. The
consent form was signed a median of 6 days after the
initial discussions about the trial and a quarter signed
during the ﬁrst consultation. There was considerable
variation in the proportion of correct answers across
individual questions in the QuIC.
Bergenmar et al12 used the QuIC to survey 282
patients who had been informed in Swedish about a
phase 2 or phase 3 trial and had signed a consent form.
The patients were asked about the duration of the
consent discussion. Thirty-nine patients (14%) reported
the duration of the consent discussion was <15 min, 139
patients (50%) responded between 15 and 30 min, and
50 patients (11%) between 45 and 60 min. The propor-
tion of correct responses to the 16 items applicable to
all patients, irrespective of trial phase was presented.
High levels of knowledge (>80%) were found for seven
items, and ﬁve items were responded to correctly by
50–80% of the patients. In total, <50% responded cor-
rectly to four items, namely risks related to the trial, the
unproven nature of the trial and issues about insurances
in connection to participating in the trial.
We used the QuIC to survey patients with cancer in
Sydney and Melbourne who had been approached to
participate in a clinical trial. The mean score on part A
of the QuIC among 100 patients studied in Sydney was
76.8.13 In 72 patients with cancer studied in Melbourne,
the median objective knowledge score was 77.6/100,
and perceived (subjective) understanding (QuIC part B)
score was 91.5.3 Some questions were answered particu-
larly poorly. Higher knowledge score (QuIC part A) was
associated with English as a ﬁrst language. Calculation of
the summary score questions included is presented
in http://jnci.oxfordjournals.org/content/93/2/139.full.
This also shows the questions that are not scored for par-
ticular phase trials.
We developed a targeted QPL for clinical trials in
order to identify questions which might facilitate patient
participation in clinical trial discussions with their
oncologist and clinical trial nurse.14 We conducted a
series of focus groups with patients with cancer and
their carers. The focus groups were audio-taped and
transcribed. The transcripts were analysed using rigorous
qualitative methodology. The ﬁnal draft of the QPL was
pilot tested to evaluate content validity, and acceptability
and perceived efﬁcacy in satisfying information needs
about clinical trials needs and achieving involvement
preference using a sample of 10 patients with cancer
considering participation in a phase 3 clinical trial at
each of the participating institutions. The clinicians,
oncologists and clinical research nurses were encour-
aged to endorse and refer to the QPL during their dis-
cussion. Feedback from these patient/clinician cohorts
informed the ﬁnal version of the clinical trial QPL. The
ﬁnal version of the clinical trial QPL used in the rando-
mised trial includes 51 questions grouped under 10
headings is presented in ﬁgure 1.
The aims of this study were to determine whether pro-
viding patients who are considering clinical trial partici-
pation with a QPL about clinical trials enhances: (1) the
patient’s quality of understanding of the cancer clinical
trial; (2) patient achievement of his or her involvement/
participation preference, (3) patient satisfaction with the
informed consent to treatment decision-making process
and (4) oncologist and research nurse satisfaction with
the clinical trial discussion and decision-making process.
We hypothesised that patients with cancer receiving a
clinical trial QPL which was endorsed by the oncologist
and trial nurse prior to deciding whether to participate
in a randomised cancer clinical trial compared with
patients not receiving this intervention would have a
higher mean knowledge score in the informed consent
questionnaire (QuIC part A) (primary outcome); have
enhanced achievement of their information and involve-
ment/participation preference; and, be more satisﬁed
with the informed consent and decision-making process.
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We also hypothesised that the intervention would not
reduce clinical trial participation.
METHODS
All patients invited to participate in a randomised
cancer treatment clinical trial at three participating
cancer centres were eligible for the study evaluating use
of the clinical trial QPL unless the cancer treatment
protocol excluded patients entered in a second rando-
mised trial. Eligible patients were approached by a
research nurse prior to their written consent to the
cancer treatment trial being sought and invited to par-
ticipate in the evaluation of the clinical trial question
prompt list. After their written consent had been
obtained, patients completed a questionnaire containing
measures of information and involvement prefer-
ences,15 16 their attitudes to clinical trials17 and their
anxiety level18 (see online supplementary appendix 1).
A randomisation sequence was generated by an inde-
pendent service. Patients were randomised by opening a
numbered blank envelope containing the treatment
group allocation: to receive or not receive the clinical
trial QPL. Patients in the control group continued their
discussion with the oncologist/research nurse about the
clinical treatment trial. Patients randomised to receive
the clinical trial QPL had at least a few minutes to
review it before continuing discussion with their oncolo-
gist and/or clinical research nurse about the cancer trial
proposed. During this latter discussion the clinicians
speciﬁcally referred to the QPL and encouraged patients
to review the list of questions. Thus participants were
not blinded to intervention assignment; however, data
entry personnel were blinded. There was no control of
QPL exposure time nor was the time documented.
There was no researcher control of items in the QPL
raised by the patient or clinician.
After the decision about cancer treatment clinical trial
participation, and within 3 weeks, patients were asked to
complete the QuIC2 and questionnaires measuring
anxiety,18 their satisfaction with the consent discussion
and decision making19 and achievement of their infor-
mation and involvement preferences.20 Clinician satisfac-
tion with the informed consent process was measured
using an adapted form of an existing seven-item scale
measuring physician satisfaction with the decision-
making process21 22 (see online supplementary
appendix 2).
The primary outcome measure was the QuIC. Part A
of this scale contains questions covering 13 domains
which are summed to produce a total score capped at
100. The authors of the QuIC reported a mean total
score of 79.7 and SD of 7.7 on part A of the scale. An
improvement of understanding of one entire domain
score is considered to be a clinically signiﬁcant improve-
ment. A sample of 130 patients was sought for the study
to have 80% power at the 5% two-sided level of signiﬁ-
cance to detect a clinically meaningful difference.
Figure 1 Questions you may wish to ask your doctor about clinical trials. This question prompt list is intended to help you to
make a decision about participating in a cancer clinical trial. It provides you with some questions that you might like to think about
and ask your doctor now or later.
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The trial accrued slowly and was stopped after 88
patients had been randomised on the advice of an inde-
pendent data monitoring committee who determined
that the probability of detecting a clinically meaningful
difference with continued recruitment was very low
(ie, the conditional power at this point in the study was
well under 20%).
Eighty-eight patients were enrolled of whom 43 were
males and 45 received the clinical trial QPL. Fifty-one
were recruited from Royal Prince Alfred Hospital, 28 from
Peter MacCallum Cancer Centre and nine from Royal
Adelaide Hospital. Table 1 presents demographic and
disease details including the clinical treatment trial inter-
vention, participating hospital and randomisation group.
Patients’ attitudes to clinical trials,15 clinical trial knowl-
edge score,21 22 and status of completed questionnaires
are also presented. Participants were balanced for gender,
marital status and education level. Seventy patients com-
pleted all relevant questionnaires, but 13 in the control
arm and ﬁve in the intervention arm did not complete
the ﬁrst and/or second questionnaires (ﬁgure 2).
Table 2 presents the results of the QuIC scores, and
the Spielberger State Anxiety Inventory.18 Twenty-eight
of 43 patients in the control arm compared with 39 of
45 receiving the clinical trial QPL completed the
informed consent questionnaire (p=0.02). There were
no signiﬁcant differences in the QuIC scores between
the randomised groups (QuIC part A p=0.08 and QuIC
part B p=0.92). We tested whether patient age or gender
modiﬁed the effect of the QPL on the QuIC, and found
no statistical evidence for this.
There was no difference in anxiety between the rando-
mised groups.
Table 3 presents the results of patient satisfaction with
the decision scores. There is no difference between the
randomised groups in these results.
Table 4 presents the results of physician satisfaction with
the consultation and with decision scores. There is no dif-
ference between the randomised groups in these results.
Table 1 Patient demographic, randomisation group,










Female 25 (56%) 20 (47%)
Marital status
Never married 5 (11%) 7 (16%)
Married/de facto 30 (67%) 30 (70%)
Widowed 2 (4%) 3 (7%)
Divorced/separated 7 (16%) 3 (7%)
Other 1 (2%) 0 (0%)
Education
Year 10 or below 18 (41%) 16 (37%)
Year 12 6 (14%) 12 (28%)
Certificate/diploma 10 (23%) 8 (19%)
University degree 5 (11%) 7 (16%)
Higher degree/postgraduate 5 (11%) 0 (0%)
Country of birth
Australia 38 (84%) 40 (93%)
Other 3 (7%) 0 (0%)
Croatia 1 (2%) 0 (0%)
Italy 0 (0%) 1 (2%)
Hungary 1 (2%) 0 (0%)
UK 1 (2%) 1 (2%)
New Zealand 0 (0%) 1 (2%)
Poland 1 (2%) 0 (0%)
Hospital
RPAH 26 (58%) 25 (58%)
PETER MAC 15 (33%) 13 (30%)





Adjuvant surgery 12 15
Adjuvant radiation 8 7
Specialist who was involved in the trial discussion
Medical oncologist 20 (44%) 23 (53%)
Surgeon 16 (36%) 15 (35%)
Radiation oncologist 6 (13%) 4 (9%)


























No 40 (89%) 30 (70%)
Did not complete
questionnaire
0 (0%) 3 (7%)
Second questionnaire not
completed
5 (11%) 10 (23%)
Peter Mac, Peter MacCallum Cancer Centre; RPAH, Royal Prince
Alfred Hospital.
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DISCUSSION
Use of the clinical trial QPL did not signiﬁcantly change
patient knowledge scores measured by the QuIC. The
percentage of patients in the control arm completing
the QuIC was signiﬁcantly reduced compared with the
intervention group (p=0.02). There was a trend towards
lower knowledge scores (QuIC part A) in the interven-
tion group compared with control (p=0.08). The reason
for this is unknown. Patients in the control group who
actually completed the assessment achieved favourable
results. We hypothesise that those in the control group
who comprised 28 of 43 patients in the control arm con-
stituted a self-selected cohort of patients who were more
engaged in the clinical trial process.
We have no information about the duration of the
consent interviews in our trial, but it is likely that use of
the clinical trial QPL extended the consent interview by
a few minutes. Patients only had the QPL for a few
minutes before continuing with the clinical trial consent
discussion so the ‘dose’ of the QPL may be low, and
therefore not effective. Physician endorsement of QPL
use by the patient in other contexts has been an import-
ant contributor to the efﬁcacy of QPLs.23 24 As QPLs
have previously demonstrated beneﬁt, it may have been
these exposure and endorsement factors that prevented
efﬁcacy of the clinical trial QPL in this instance.
The patients in our trial all consented to participate in
the informed consent trial at the ﬁrst consultation when
trial participation was sought. This ﬁnding differs from
the experience reported by Joffe et al2 where the consent
form for the treatment trial was signed a median of 6 days
after the initial discussion about the trial, and only 28%
consented at the ﬁrst consultation. There is great vari-
ation in the interval from considering participation in a
clinical trial to consenting to enrol in the trial. We do not
know when patients consented to participate in the
cancer treatment trial but patients were asked to com-
plete the QuIC within 3 weeks after the decision about
cancer trial participation had been made.
Stryker et al25 studied the factors associated with
informed consent, patient satisfaction, and decisional
Table 2 Results of the QuIC scores, and the Spielberger State Anxiety Inventory18
Measure Intervention Control Difference (95% CI) p Value*
QuIC part A summary
N 39 28




QuIC part B summary
N 39 28




Spielberger State Anxiety Inventory (follow-up)
N 38 26





QuIC, Quality of Informed Consent questionnaire.
Figure 2 Participant flow diagram.
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regret in 87 patients who were eligible to participate in
12 selected phase 1, 2 and 3 clinical trials. They found
that patients who enrolled in clinical trials quickly, may
not believe they fully understand the implications of
trial participation and ultimately regret their decision to
participate. However, there was no relationship between
timing of consent and decisional regret.
Limitations of the study include the low accrual rate,
the imbalance in completion of the QuIC in the
randomised groups and the brief exposure to the clin-
ical trial QPL. Future studies of clinical trial question
prompt lists should document the duration of the
consent interview, the time taken for consent to be
given, and consideration of when is the optimal time
for patient understanding of their clinical trial to be
sought.
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Table 3 Patient satisfaction with decision scores
Measure Intervention Control p Value*
Adequately informed
Disagree strongly 0 (0%) 1 (4%)
I disagree 1 (3%) 0 (0%)
Neutral 2 (5%) 2 (7%)
Agree 20 (51%) 12 (43%)
Agree strongly 16 (41%) 13 (46%)
Total 39 28 0.6315
Best decision
Disagree strongly 0 (0%) 1 (4%)
I disagree 1 (3%) 0 (0%)
Neutral 3 (8%) 3 (11%)
I agree 13 (33%) 10 (36%)
Agree strongly 22 (56%) 14 (50%)
Total 39 28 0.6575
Consistent with values
Disagree strongly 0 (0%) 1 (4%)
Neutral 5 (13%) 3 (11%)
I agree 17 (35%) 12 (43%)
Agree strongly 16 (42%) 12 (43%)
Total 38 28 0.6935
Carry out decision
Disagree strongly 0 (0%) 1 (4%)
Neutral 2 (5%) 0 (0%)
I agree 17 (46%) 14 (50%)
Agree strongly 18 (49%) 13 (46%)
Total 37 28 0.4063
I am satisfied this was my decision to make
Disagree strongly 0 (0%) 1 (4%)
Neutral 2 (5%) 1 (4%)
I agree 13 (33%) 14 (50%)
Agree strongly 24 (62%) 12 (43%)
Total 39 28 0.3002
I am satisfied with my decision
Disagree strongly 0 (0%) 1 (4%)
Neutral 4 (11%) 3 (11%)
I agree 14 (37%) 11 (39%)
Agree strongly 20 (53%) 13 (46%)
Total 38 28 0.6806
*Fisher’s exact test.
Table 4 Clinical satisfaction with the consent consultation
and with decision scores
Intervention Control p Value*
I am satisfied that I provided enough information about the
treatment options
Strongly disagree 1 (2%) 2 (6%)
Not sure 1 (2%) 1 (3%)
Agree 21 (51%) 21 (58%)
Strongly agree 18 (44%) 12 (33%)
Total 41 36 0.77
I am satisfied that I clearly communicated the clinical trial
and treatment options
Strongly disagree 1 (2%) 1 (3%)
Not sure 2 (5%) 3 (8%)
Agree 20 (49%) 21 (58%)
Strongly agree 18 (44%) 11 (31%)
Total 41 36 0.68
I am satisfied that I involved the patient in the
decision-making process
Strongly disagree 1 (2%) 1 (3%)
Not sure 2 (5%) 2 (6%)
Agree 21 (51%) 21 (58%)
Strongly agree 17 (41%) 12 (33%)
Total 41 36 0.93
The patient understood the clinical trial being proposed
Strongly disagree 1 (2%) 1 (3%)
Disagree 0 (0%) 1 (3%)
Not sure 1 (2%) 3 (8%)
Agree 26 (63%) 25 (69%)
Strongly agree 13 (32%) 6 (17%)
Total 41 36 0.33
Overall, I am satisfied with the decision-making process for
this patient
Strongly disagree 2 (5%) 1 (3%)
Disagree 1 (2%) 0 (0%)
Not sure 2 (5%) 5 (14%)
Agree 22 (54%) 23 (64%)
Strongly agree 14 (34%) 7 (19%)
Total 41 36 0.32
*Fisher’s exact test.
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